<DOC>
	<DOCNO>NCT02265705</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know baricitinib participant moderately severely active rheumatoid arthritis inadequate response methotrexate therapy .</brief_summary>
	<brief_title>A Study Baricitinib ( LY3009104 ) Participants With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have diagnosis adultonset RA define ACR/European League Against Rheumatism ( EULAR ) 2010 Criteria Classification RA . Have moderately severely active RA define presence least 6/68 tender joint least 6/66 swollen joint . Have CRP ( hsCRP ) measurement â‰¥ 6 mg/liter ( L ) base recent data ( available ) . Have regular use MTX least 12 week prior study entry dose , accordance local clinical practice , consider acceptable adequately assess clinical response . The dose MTX must stable , unchanging oral dose 7.5 25 mg/week ( equivalent injectable dose ) least 8 week prior study entry . The dose MTX expect remain stable throughout study may adjust safety reason . Are currently receive corticosteroid dos &gt; 10 mg prednisone per day ( equivalent ) receive unstable dose regimen corticosteroid within 2 week study entry within 6 week plan randomization . Have start treatment NSAIDs within 2 week study entry within 6 week plan randomization receive unstable dose regimen NSAIDs within 2 week study entry within 6 week plan randomization . Are currently receive concomitant treatment MTX , hydroxychloroquine , sulfasalazine combination 3 conventional disease modify antirheumatic drug ( cDMARDs ) . Are currently receive receive cDMARDs ( example , gold salt , cyclosporine , azathioprine , immunosuppressive ) MTX , hydroxychloroquine ( 400 mg/day ) , sulfasalazine ( 3000 mg/day ) within 8 week prior study entry . Have receive leflunomide 12 week prior study entry ( within 4 week prior study entry standard 11 day cholestyramine use washout leflunomide ) . Have start new physiotherapy treatment RA 2 week prior study entry . Have ever receive biologic DMARD ( tumor necrosis factor ( TNF ) , interleukin1 , interleukin6 ( IL6 ) , Tcell Bcelltargeted therapy ) . Have receive parenteral corticosteroid administer intramuscular intravenous injection within 2 week prior study entry within 6 week prior plan randomization anticipate require parenteral injection corticosteroid study . Have 3 joint injected intraarticular corticosteroid hyaluronic acid within 2 week prior study entry within 6 week prior plan randomization . Have diagnosis systemic inflammatory condition RA , limit , juvenile chronic arthritis , spondyloarthropathy , Crohn 's disease , ulcerative colitis , psoriatic arthritis , active vasculitis gout . Have estimate glomerular filtration rate ( eGFR ) base recent available serum creatinine use Modification Diet Renal Disease ( MDRD ) method &lt; 40 milliliters/minute/1.73 meter square ( m^2 ) . Have history chronic liver disease recent available aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal ( ULN ) recent available total bilirubin 1.5 time ULN . Have current recent ( &lt; 30 day prior study entry ) clinically serious viral , bacterial , fungal , parasitic infection . Have history active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) . Have household contact person active tuberculosis ( TB ) receive appropriate document prophylaxis TB . Have evidence active TB previously evidence active TB receive appropriate document treatment . Are pregnant nursing time study entry . Are females childbearing potential agree use 2 form highly effective birth control engage intercourse enrol study least 28 day follow last dose orally administer investigational product . Are male agree use 2 form highly effective birth control engage sexual intercourse female partner childbearing potential enrol study least 28 day follow last dose orally administer investigational product . Have previously randomize study study investigate baricitinib . Have receive prior treatment oral janus kinase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>